Cromos Pharma Announces the Opening of a New Office in Portugal
Cromos Pharma has opened a new office in Lisbon, Portugal, expanding its presence in Southern Europe. Portugal’s robust healthcare system, EU regulatory alignment, and diverse patient population make it an ideal site for clinical trials. This expansion bolsters Cromos Pharma’s European operations and underscores its commitment to patient-centered research, offering its "No Patients – No Payment" model to minimize sponsor risk. - September 17, 2024
Pioneering Cancer Treatment: the Successful Partnership Between MAIA Biotechnology and Cromos Pharma
MAIA Biotechnology, a leader in targeted therapy and immuno-oncology, partnered with Cromos Pharma, an international CRO, to advance cancer treatment. At ASCO 2024, MAIA unveiled promising interim data for THIO, a telomere-targeting agent for NSCLC, showing an 85% disease control rate with THIO and Libtayo in advanced patients. Cromos excelled in patient recruitment and regulatory approvals in key European countries. This collaboration underscores their commitment to revolutionizing cancer care. - June 22, 2024